Qingdao Jiulong Biopharmaceutical Co., Ltd was founded in Nov, 1998. The registered capital is 100 million RMB. Company has 3 subsidiaries ,such as Kangyuan Pharmaceutical Co. Ltd., Qingdao Pharmax Pharmaceutical Co., Ltd. and Qingdao Guanlong Pharmaceutical Co., Ltd.. Company already set up a complete industrial chain which products are extracted from basic materials, such as human urine, porcine intestinal mucosa and marine organism organ, to be proceeded into purified API, finally to be preparations.
Inthecompetitivearenaofthepharmaceuticalindustry,a
Inthecomplexandcriticalfieldofpharmaceuticals,hepa
Heparinsodiumisthefirstchoicedrugforanticoagulantd
ThecompanyproductionofdalteparinsodiumAPIconformst
TheenoxaparinheparinsodiumAPIcomformstotherequirem
From raw materials purchasing , producing, to quality inspection, delivery, each process is responsible by professional staff, we are a powerful team organization.Give your trust to us, we will give you a pleasant surprise.
The company has introduced advanced production equipment from Germany to ensure large-scale production of products, greatly improved output, shortened production period and improved product quality.
The company has professional quality inspection team and testing equipment , from raw materials purchasing to producing, packaging , every process are tested strictly to ensure product quality, our products can accept testing by third party.
Globaldemandforanticoagulantpharmaceuticalskeepsrisingamidgrowingcasesofvenousthrombosis,cardiovascularsurgeryanddialysistreatment.Unfractionatedhepar
Chronicthrombosispreventionandlong-termdialysisanticoagulationfuelsteadydemandsforspecializedlowmolecularweightheparinAPIsworldwide.DalteparinSodiumst
GloballowmolecularweightheparinsupplychainsfacestricterregulatorychecksacrossEuropeandNorthAmericain2026.Mostpharmaceuticalwholesalersandinjectabledru
Theglobaljointhealthnutraceuticalmarketmaintainssteadygrowth.Clean-labelproductionandlow-residueindicatorshavebecomemandatoryprocurementthresholdsforh
Globalanticoagulantpharmaceuticalsupplychainsfacerisingqualitysupervisionin2026.MorepharmaceuticalfactoriesandrawmaterialdistributorsfocusonqualifiedH
Theglobalmarketforlong-termclinicallowmolecularweightheparintreatmentkeepsexpanding,withcancer-relatedthrombosis,chronichemodialysisandelderlypostoper
Globalpharmaceuticalrawmaterialmarketsarefacingfrequentrawmaterialcostfluctuationsandunstablesupplychains,makingreasonableHeparinSodiumPriceandstablep
Thegloballowmolecularweightheparinpharmaceuticalindustrycontinuestoraisehigherstandardsforclinicalsafetyandbatchconsistency,drivingsurgingdemandforref